Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar will speak in the Water Tower Research Fireside Chat on Monday, December 15, 2025 at 1:00 PM ET.
The discussion will cover the final data from Anixa's Phase 1 breast cancer vaccine trial (to be presented December 11, 2025 at the San Antonio Breast Cancer Symposium), the implications of the retired protein strategy for cancer vaccines, and next steps for vaccine development. The event is open to investors and registration is available through Water Tower Research.
Positive
- None.
Negative
- None.
News Market Reaction – ANIX
In the Dec 10 session, ANIX gained 1.38%, reflecting a mild positive market reaction. Argus tracked a peak move of +33.6% during that session. Argus tracked a trough of -15.4% from its starting point during tracking. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 5.0x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 17 | CAR-T naming milestone | Positive | +2.2% | WHO approval of INN for FSHR-targeted CAR-T ovarian cancer therapy. |
| Nov 12 | Patent extension | Positive | -4.6% | Key U.S. patent extending breast cancer vaccine IP into mid-2040s. |
| Nov 10 | Investor fireside chat | Neutral | +0.0% | Announcement of investor fireside chat covering programs and trial status. |
| Nov 5 | Data transfer deal | Positive | +2.5% | Data transfer agreement and plan to move breast cancer vaccine to Phase 2. |
| Oct 23 | Investor conference | Positive | +3.5% | Planned presentation at Spartan Capital investor conference to reach new investors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has been largely positive (IP, trial progress, WHO naming), with price reactions mostly modestly positive or flat and one notable negative move on a positive patent update, indicating occasionally inconsistent alignment between upbeat news and near-term price action.
Over the last few months, Anixa reported several milestones across its programs. On Nov 5, 2025, it executed a data transfer agreement to assume IND sponsorship and advance its breast cancer vaccine to Phase 2, with encouraging Phase 1 immune-response data and final results slated for Dec 11, 2025 (stock +2.52%). A new WHO International Nonproprietary Name for its ovarian cancer CAR-T therapy on Nov 17, 2025 saw a 2.19% gain. A patent win on breast cancer vaccine IP led to a 4.57% decline, showing that positive developments have produced mixed short-term reactions.
Key Terms
phase 1 medical
breast cancer vaccine medical
cancer vaccines medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Fireside Chat will be hosted by Robert Sassoon, Managing Director – Healthcare at Water Tower Research, and will cover several topics, including:
- The final data from Anixa's Phase 1 breast cancer vaccine trial—data which will have been presented on December 11, 2025, at the San Antonio Breast Cancer Symposium
- Implications for the application of the retired protein strategy for cancer vaccines
- Next steps for vaccine development
This event is open access for all investors to participate. Interested parties can register for the event through Water Tower Research at: Webinar Registration - Zoom
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-participate-in-water-tower-research-fireside-chat-on-monday-december-15-2025-302637196.html
SOURCE Anixa Biosciences, Inc.